Servier agreed to acquire Day One Biopharmaceuticals for approximately $2.5 billion in cash, taking ownership of Day One’s marketed pediatric glioma therapy Ojemda (tovorafenib) and its broader oncology pipeline. The transaction values Day One at $21.50 per share and is expected to close in the second quarter. Day One reported roughly $155 million in Ojemda sales in 2025; Servier said the asset complements its existing glioma and rare oncology portfolio, including Voranigo. Servier plans to fund the deal with cash and investments and cited the acquisition as part of a push to expand in rare cancers. David Lee, Servier U.S. CEO, framed the buy as a strategic lift to both commercial reach and development capacity for pediatric and adult solid‑tumor programs.